In reply. QTc prolongation and delamanid: access and safety.


The mean QTcF increase was 12.1 ms in the total DLMþOBR group (n 1⁄4 161),4 and 10.7 ms in the DLMþOBR subset receiving LVX for at least 1 month (n 1⁄4 91). Only two DLMþOBR patients received CFZþLVX during the trial; neither had an event of QTcF prolongation reported. In Trials 204 and 208, QTcF prolongation in DLM-treated patients reached its peak by week… (More)
DOI: 10.5588/ijtld.15.0541-2


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics